Maoshan Chen
Rong Xu
Jing Zhang
Andrew Spencer
Richard Simpson5- 1Laboratory of Radiation Biology, Department of Blood Transfusion, Laboratory Medicine Centre, The Second Affiliated Hospital, Army Medical University, Chongqing, China
- 2Nanobiotechnology Laboratory, Australian Centre for Blood Diseases, Monash University/Alfred Health, Melbourne, VIC, Australia
- 3Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- 4Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC, Australia
- 5Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science (LIMS), School of Agriculture, Biomedicine and Environment, La Trobe University, Melbourne, VIC, Australia
Editorial on the Research Topic
Understanding the RNA Species in the Extracellular Vesicles of Multiple Myeloma
Multiple myeloma (MM) is a multi-focal plasma cell malignancy that develops at diverse sites throughout the bone marrow (BM) compartment (1). Despite advances in therapy in the past 15 years, MM remains incurable with a remitting relapsing clinical course and the invariable development of disease that is refractory to all available therapies. Emerging evidence has implicated extracellular vesicles (EVs), heterogeneous nano-sized lipid-bound organelles shed by most cells into the extracellular space (2), in MM pathogenesis, including angiogenesis, osteolysis, immune suppression environment and drug resistance (3). Based on their size, EVs comprise three major classes – exosomes (30 ~150 nm, of endocytic origin), shed midbody remnants (which arise from symmetrical abscission of the midbody during the late stage of cytokinesis) and shed microvesicles (50 ~ 1500 nm, aka microparticles, which arise from blebbing of the plasma membrane), and can transfer DNA fragments, RNAs, proteins, lipids and metabolites to both neighbouring and distant cells (2).
This Research Topic aims to bring together clinical and basic scientists, and summarise our understanding of the roles of EV RNA molecules (e.g., microRNA, mRNA, circular RNA, long non-coding RNA) in MM. And although this area has been studied in many solid tumours, it is a relatively new area of investigation in MM. True to its aim, this special issue has included two review articles that highlight some of the most recent advances regarding the identification, characterization, and function of EV RNAs in MM pathogenesis and potential translational applications.
The BM tumour microenvironment (TME) is a critical mediator of growth and survival for MM plasma cells. In this context, Khalife et al. for the first time have demonstrated the effects of MM-EV-derived RNAs on a range of TME compartments (e.g., hematopoietic cells, mesenchymal stromal cells (MSC), endothelial cells, immune cells, osteoclasts, and osteoblasts) all of which are understood to play a role in MM pathology. These include plasma cell proliferation, escape from immune surveillance, angiogenesis and lytic bone disease (Khalife et al.). The tumour suppressor miR-15a can be transferred by the MM-BM-MSC EVs into the MM plasma cells and activates the AKT pathway, promoting proliferation, survival, and migration of MM cells (4, 5). Similarly, miR-10a and the long non-coding RNA LINCOO461 can be transferred to MM cells via MSC EVs and induce the proliferation of MM cells (6, 7). EV RNAs also play an important role in the inhibition of osteoblast development, osteoclast differentiation, and their bone resorption activity, such as miR-103-3p (8), miR-129 (9) and DKK-1 mRNA (10).
In another contribution, Reale et al. have summarised the translational applications of MM-derived EV RNAs, including in relation to drug resistance, liquid biomarkers, and therapeutic strategies (Reale et al). By comparing the RNA profiles of EVs isolated from the serum and plasma of MM patients and healthy individuals, several RNAs have been suggested as potential clinical biomarkers, including microRNAs (e.g., miR-155, miR-34a, let-7, miR-20a, miR-103a, miR-185, miR-425, miR-4505, miR-4741), mRNA transcripts (e.g., PSMA3), and long non-coding RNAs (e.g., PRINS, PSMA3-AS1). Regarding potential therapeutic applications, c-Myc and TGF-β1 were targeted with RNA-armed EVs or engineered EV-like nanoparticles for the transfer of siRNAs, shRNAs, and antisense oligonucleotides into the lymphoma models (11–13). However, proof of concept of EV-RNA-engineered therapy for MM is still warranted. In this Research Topic, both Khalife et al. and Reale et al. agreed that EVs can be purified from both biofluids of MM patients and cell culture supernatants; however, the standardization of isolation protocols and criteria for characterizing purified MM-derived EVs is still essential for lab-to-lab comparisons (Khalife et al.; Reale et al.).
In conclusion, the articles collected in this Research Topic provide a series of insightful datasets to better understand the biological functions and translational applications of RNA molecules in the MM-derived EVs. However, further studies investigating the roles of MM-EV RNA in vivo are required. We trust that the high-quality information published in this issue of Frontiers in Oncology will be of interest to researchers in the fields of MM pathogenesis, biomarkers, and therapeutics.
Author Contributions
MC –prepared the first version of the editorial. MC, RX, JZ, AS and RJ - discuss the editorial content and revised the final editorial text. All authors contributed to the article and approved the submitted version.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Chen M, Mithraprabhu S, Ramachandran M, Choi K, Khong T, Spencer A. Utility of Circulating Cell-Free RNA Analysis for the Characterization of Global Transcriptome Profiles of Multiple Myeloma Patients. Cancers (2019) 11(6):887.
2. Xu R, Rai A, Chen M, Suwakulsiri W, Greening DW, Simpson RJ. Extracellular Vesicles in Cancer—Implications for Future Improvements in Cancer Care. Nat Rev Clin Oncol (2018) 15(10):617–38.
3. Menu E, Vanderkerken K. Exosomes in Multiple Myeloma: From Bench to Bedside. Blood (2022). doi: 10.1182/blood.2021014749
4. Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, et al. BM Mesenchymal Stromal Cell-Derived Exosomes Facilitate Multiple Myeloma Progression. J Clin Invest (2013) 123(4):1542–55. doi: 10.1172/JCI66517
5. Wang J, Hendrix A, Hernot S, Lemaire M, De Bruyne E, Van Valckenborgh E, et al. Bone Marrow Stromal Cell-Derived Exosomes as Communicators in Drug Resistance in Multiple Myeloma Cells. Blood (2014) 124(4):555–66. doi: 10.1182/blood-2014-03-562439
6. Deng M, Yuan H, Liu S, Hu Z, Xiao H. Exosome-Transmitted LINC00461 Promotes Multiple Myeloma Cell Proliferation and Suppresses Apoptosis by Modulating microRNA/BCL-2 Expression. Cytotherapy (2019) 21(1):96–106. doi: 10.1016/j.jcyt.2018.10.006
7. Umezu T, Imanishi S, Yoshizawa S, Kawana C, Ohyashiki JH, Ohyashiki K. Induction of Multiple Myeloma Bone Marrow Stromal Cell Apoptosis by Inhibiting Extracellular Vesicle miR-10a Secretion. Blood Adv (2019) 3(21):3228–40. doi: 10.1182/bloodadvances.2019000403
8. Zhang L, Lei Q, Wang H, Xu C, Liu T, Kong F, et al. Tumor-Derived Extracellular Vesicles Inhibit Osteogenesis and Exacerbate Myeloma Bone Disease. Theranostics (2019) 9(1):196–209. doi: 10.7150/thno.27550
9. Raimondo S, Urzi O, Conigliaro A, Bosco GL, Parisi S, Carlisi M, et al. Extracellular Vesicle microRNAs Contribute to the Osteogenic Inhibition of Mesenchymal Stem Cells in Multiple Myeloma. Cancers (Basel) (2020) 12(2):449. doi: 10.3390/cancers12020449
10. Faict S, Muller J, De Veirman K, De Bruyne E, Maes K, Vrancken L, et al. Exosomes Play a Role in Multiple Myeloma Bone Disease and Tumor Development by Targeting Osteoclasts and Osteoblasts. Blood Cancer J (2018) 8(11):105. doi: 10.1038/s41408-018-0139-7
11. Lunavat TR, Jang SC, Nilsson L, Park HT, Repiska G, Lasser C, et al. RNAi Delivery by Exosome-Mimetic Nanovesicles - Implications for Targeting C-Myc in Cancer. Biomaterials (2016) 102:231–8. doi: 10.1016/j.biomaterials.2016.06.024
12. Huang F, Wan J, Hu W, Hao S. Enhancement of Anti-Leukemia Immunity by Leukemia-Derived Exosomes Via Downregulation of TGF-Beta1 Expression. Cell Physiol Biochem (2017) 44(1):240–54. doi: 10.1159/000484677
Keywords: Multiple myeloma, Extracellular vesicles, Exosomes, Liquid biopsy, Tumour microenvironment
Citation: Chen M, Xu R, Zhang J, Spencer A and Simpson R (2022) Editorial: Understanding the RNA Species in the Extracellular Vesicles of Multiple Myeloma. Front. Oncol. 12:946160. doi: 10.3389/fonc.2022.946160
Received: 17 May 2022; Accepted: 19 May 2022;
Published: 23 June 2022.
Edited and reviewed by:
Tao Liu, University of New South Wales, AustraliaCopyright © 2022 Chen, Xu, Zhang, Spencer and Simpson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Maoshan Chen, bWFvc2hhbmNoZW5AZ21haWwuY29t